- CA$765.64m
- CA$1.14bn
- $724.34m
- 65
- 95
- 58
- 86
Annual balance sheet for Cresco Labs, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Interim Report | ARS | ARS | ARS | ARS |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 136 | 224 | 119 | 103 | 138 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 32.4 | 44.7 | 56.9 | 52.5 | 52.1 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 249 | 422 | 326 | 278 | 294 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 301 | 457 | 508 | 486 | 456 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 1,233 | 1,780 | 1,584 | 1,358 | 1,355 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 253 | 288 | 281 | 200 | 94.3 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 759 | 1,025 | 957 | 853 | 881 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 473 | 756 | 627 | 506 | 475 |
| Total Liabilities & Shareholders' Equity | 1,233 | 1,780 | 1,584 | 1,358 | 1,355 |
| Total Common Shares Outstanding |